Skip to main content
. 2015 Oct 26;32(10):888–905. doi: 10.1007/s12325-015-0244-y

Table 3.

Relevant outcomes in pregnant women with diabetes receiving ILPS or NPH insulin in a multicenter retrospective cohort study [81]

Patients Insulin (N) Age (years) Mean BMIa, kg/m2 Mean maternal HbA1c (trimester), % Maternal outcomes, % patients Pregnancy/fetal outcomes, % pregnancies Mean fetal birth weight, g
0b 1st 2nd 3rd Severe HG HTNc DKA Cesarean section Congenital malformation Macrosomia
GDM ILPS (508) 36.3 27.2 NA NA NA NA 0 6.9 0 48.7 0 5.3 3295
NPH (125) 24.9 26.0 NA NA NA NA 0 6.9 0 48.8 0 6.9 3423
T1D ILPS (37) 35.5 24.0 7.5 7.1 6.5 6.4 5.4 8.1 0 45.9 0 21.6 3550
NPH (504) 29.9 23.3 7.5 7.2 7.2 6.4 15.1 12.8 5.4 73.0 5.9 13.3 3300
T2D ILPS (67) 33.2 28.7 6.7 6.4 5.8 6.2 1.5 8.9 0 46.5 0 8.9 3235
NPH (164) 33.2 28.1 6.6 6.1 6.4 5.7 1.3 9.4 0 69.3 1.9 11.9 3200

BMI body mass index, DKA diabetic ketoacidosis, GDM gestational diabetes, HbA1c glycated hemoglobin, HG hypoglycemia, HTN hypertension, ILSP insulin lispro protamine suspension, NA not available, NPH neutral protamine Hagedorn, T1D type 1 diabetes, T2D type 2 diabetes

aPrepregnancy maternal BMI

bPreconception period

cDuring pregnancy